Catheterization and Cardiovascular Interventions
Volume 91, Issue 2 pp. 213-214
Coronary Artery Disease

Hybrid coronary revascularization: Time for a new comparator?

Naoki Misumida MD, 

Naoki Misumida MD

Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky

Search for more papers by this author
David J. Moliterno MD, 

Corresponding Author

David J. Moliterno MD

Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky

Correspondence David J. Moliterno, MD, Department of Internal Medicine, University of Kentucky, 900 S. Limestone Avenue, 329 Wethington Building, Lexington, KY 40536-0200. Email: [email protected]Search for more papers by this author
First published: 06 February 2018
https://doi.org/10.1002/ccd.27503

Key Points

  • The present meta-analysis found no significant difference between hybrid coronary revascularization (HCR) and bypass surgery (CABG) regarding intermediate-term major adverse cardiac and cerebrovascular events.
  • HCR is feasible, historically with higher revascularization rates but less perioperative morbidity
  • With a comparable frequency of repeat revascularization between current-generation drug-eluting stents and CABG, future trials of HCR are considering multi-vessel PCI as the new comparator.

CONFLICT OF INTEREST

Nothing to report.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.